Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects

Inclusion Criteria: * The participant is ≥ 18 years old * The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. * The participant has adequate organ function as follows: * Serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min. * Bilirubin ≤ the institutional upper limits of normal (ULN) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to be within institutional normal range. * Absolute neutrophil count (ANC) ≥ 1000mm³ * Platelet count ≥ 100,000/mm³ * The participant has the capability of understanding the informed consent document and has signed the informed consent document. * Sexually active participants (male and female) must use medically acceptable methods of contraception during the course of the study. * Female participants of childbearing potential must have a negative pregnancy test at screening. * Able to understand and comply with the requirements of the protocol. Exclusion Criteria: * The participant is receiving investigational therapy (other than the investigational therapy under study). * The participant has received investigational therapy within 30 days prior to first dose of study drug. * Patients who are unable to swallow capsules. * Patients with prior malignancies, other than squamous or basal cell carcinomas, unless disease free for ≥ 5 years. * The participant has had prior major surgery within 30 days prior to first dose of study drug. * The participant has active infection or fever \>38.5C within 3 days prior to first dose of study drug. * The participant has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * The participant is unable or unwilling to stop taking vitamins, herbal remedies, or nonprescription medications. * The participant is pregnant or breastfeeding. * The participant is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.